Asenapine pharmacokinetics in hepatic and renal impairment

Clinical Pharmacokinetics

Volumn 50, Issue 7, 2011, Pages 471-481

  Peeters, Pierre ^a   Bockbrader, Howard ^b   Spaans, Edwin ^c   Dogterom, Peter ^a   Lasseter, Kenneth ^d   Marbury, Thomas ^e   Gibson, Gordon L ^f   De Greef, Rik ^a  

^a NV ORGANON   (Netherlands)

^b PFIZER INC   (United States)

^c Kinesis Pharma   (Netherlands)

^d Clinical Pharmacology of Miami   (United States)

^e ORLANDO CLINICAL RESEARCH CENTER   (United States)

^f Clinical Study Centers LLC   (United States)

Author keywords

Antipsychotics; Asenapine; Liver dysfunction; Metabolites; Renal impairment

Indexed keywords

ASENAPINE; ASENAPINE N GLUCURONIDE; DRUG METABOLITE; N DESMETHYLASENAPINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DYSGEUSIA; FEMALE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY IMPAIRMENT; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER IMPAIRMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; ORAL PARESTHESIA; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CREATININE; DRUG MONITORING; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; KIDNEY; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; RENAL INSUFFICIENCY;

EID: 79958259592     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11590490-000000000-00000     Document Type: Article

References (25)

1. Saphris- (asenapine) sublingual tablets: US prescribing information [online]. Available from URL: http://www.spfiles.com/pisaphrisv1.pdf [Accessed 2011 Apr 14].
2. European Medicines Agency. Sycrest (asenapine): European public assessment report [online]. Available from URL: http://www.ema.europa.eu/ema/ index. jsp?curl=pages/medicines/human/medicines/001177/human-med-001379.jsp& murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125 [Accessed 2011 Apr 14].
3. Shahid M, Walker GB, Zorn SH, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009 Feb 28; 23 (1): 65-73.
4. Data on file, Merck & Co., Inc., 2010.
5. Dogterom P, Hulskotte E, Gerrits M, et al. Asenapine pharmacokinetics: influence of cytochrome P450 modulators and UDP-glucuronyltransferase inhibition. Eur Neuropsychopharmacol 2008; 18 (Suppl. 4): S452-3.
6. US Food and Drug Administration. Guidance for industry - pharmacokinetics in patients with impaired renal function: study design, data analysis, and impact on dosing and labeling [online]. Available from URL: http://www. fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid ances/UCM204959.pdf [Accessed 2011 Apr 14].
7. US Food and Drug Administration. Guidance for industry - pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling [online]. Available from URL: http://www. fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid ances/ucm072123.pdf [Accessed 2011 Apr 14].
8. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973 Aug; 60 (8): 646-9.
9. Dogterom P, Timmer C, de Greef HJMM, et al. A phase I study to investigate the safety, tolerability, and pharmacokinetics of single and multiple doses of sublingually administered asenapine in healthy male volunteers [abstract]. Clin Pharmacol Ther 2009; 85 (Suppl. 1): S86.
10. Prohn M, de Greef R, Chapel S, et al. Asenapine population pharmacokinetics in patients with schizophrenia or bipolar disorder. Eur Neuropsychopharmacol 2009; 19 (Suppl. 3): S542-3.
11. Dogterom P, Machielsen C, Timmer C, et al. Effect of food on the pharmacokinetics of sublingual asenapine [abstract no. 97]. J Clin Pharmacol 2010; 50 (9): 1079 [online]. Available from URL: http://jcp.sagepub.com/content/ 50/9/1058.full.pdf+html [Accessed 2011 Apr 14].
12. George J, Byth K, Farrell GC. Influence of clinicopathological variables on CYP protein expression in human liver. J Gastroenterol Hepatol 1996; 11: 33-9. (Pubitemid 26115059)
13. Takahashi H, Suzuki M, Ikeda H, et al. Evaluation of quantitative portal venous, hepatic arterial, and total hepatic tissue blood flow using xenon CT in alcoholic liver cirrhosis: comparison with liver cirrhosis related to hepatitis C virus and nonalcoholic steatohepatitis. Alcohol Clin Exp Res 2010 Feb; 34 Suppl. 1: S7-13.
14. Mallikaarjun S, Shoaf SE, Boulton DW, et al. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Clin Pharmacokinet 2008; 47 (8): 533-42. (Pubitemid 351969827)
15. Zyprexa (olanzapine): US prescribing information [online]. Available from URL: http://pi.lilly.com/us/zyprexa-pi.pdf [Accessed 2011 Apr 14].
16. Thyrum PT, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry 2000 May; 24 (4): 521-33. (Pubitemid 30419077)
17. Aweeka F, Jayesekara D, Horton M, et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol 2000; 49 Suppl. 1: 27S-33S. (Pubitemid 30151050)
18. Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl) 1995 Dec; 122 (3): 223-9.
19. Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med 2006 Nov; 21 (11): 1133-7. (Pubitemid 44506864)
20. Carney CP, Jones LE. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med 2006 Sep- Oct; 68 (5): 684-91. (Pubitemid 44454636)
21. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007 Oct; 68 (10): 1492-500. (Pubitemid 350073395)
22. Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2010; 30 (2): 106-15.
23. McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009 Nov; 11 (7): 673-86.
24. McIntyre RS, Cohen M, Zhao J, et al. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord 2009 Dec; 11 (8): 815-26.
25. McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010 Apr; 122 (1-2): 27-38